Logo image of BCAB

BIOATLA INC (BCAB) Stock Fundamental Analysis

NASDAQ:BCAB - Nasdaq - US09077B1044 - Common Stock - Currency: USD

0.4081  -0.04 (-9.03%)

After market: 0.426 +0.02 (+4.39%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BCAB. BCAB was compared to 571 industry peers in the Biotechnology industry. BCAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BCAB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BCAB had negative earnings in the past year.
BCAB had a negative operating cash flow in the past year.
In the past 5 years BCAB always reported negative net income.
BCAB had a negative operating cash flow in each of the past 5 years.
BCAB Yearly Net Income VS EBIT VS OCF VS FCFBCAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -131.46%, BCAB is not doing good in the industry: 82.59% of the companies in the same industry are doing better.
With a Return On Equity value of -356.22%, BCAB is not doing good in the industry: 76.91% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -131.46%
ROE -356.22%
ROIC N/A
ROA(3y)-62.62%
ROA(5y)-102.28%
ROE(3y)-93%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCAB Yearly ROA, ROE, ROICBCAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCAB Yearly Profit, Operating, Gross MarginsBCAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -10K -20K -30K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, BCAB has more shares outstanding
The number of shares outstanding for BCAB has been increased compared to 5 years ago.
BCAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCAB Yearly Shares OutstandingBCAB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
BCAB Yearly Total Debt VS Total AssetsBCAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

BCAB has an Altman-Z score of -13.84. This is a bad value and indicates that BCAB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -13.84, BCAB is not doing good in the industry: 80.64% of the companies in the same industry are doing better.
There is no outstanding debt for BCAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.84
ROIC/WACCN/A
WACCN/A
BCAB Yearly LT Debt VS Equity VS FCFBCAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 3.11 indicates that BCAB has no problem at all paying its short term obligations.
BCAB has a Current ratio of 3.11. This is in the lower half of the industry: BCAB underperforms 63.41% of its industry peers.
A Quick Ratio of 3.11 indicates that BCAB has no problem at all paying its short term obligations.
BCAB has a Quick ratio of 3.11. This is in the lower half of the industry: BCAB underperforms 61.63% of its industry peers.
Industry RankSector Rank
Current Ratio 3.11
Quick Ratio 3.11
BCAB Yearly Current Assets VS Current LiabilitesBCAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.09% over the past year.
EPS 1Y (TTM)36.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.71% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y40.27%
EPS Next 2Y21.82%
EPS Next 3Y13.83%
EPS Next 5Y10.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCAB Yearly Revenue VS EstimatesBCAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
BCAB Yearly EPS VS EstimatesBCAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCAB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCAB Price Earnings VS Forward Price EarningsBCAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCAB Per share dataBCAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

BCAB's earnings are expected to grow with 13.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.82%
EPS Next 3Y13.83%

More info and screens

0

5. Dividend

5.1 Amount

BCAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOATLA INC

NASDAQ:BCAB (2/21/2025, 8:02:52 PM)

After market: 0.426 +0.02 (+4.39%)

0.4081

-0.04 (-9.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-20 2025-03-20/amc
Inst Owners48.4%
Inst Owner Change-93.61%
Ins Owners6.05%
Ins Owner Change-0.09%
Market Cap23.68M
Analysts82.22
Price Target9.69 (2274.42%)
Short Float %8.24%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.8%
Min EPS beat(2)1.51%
Max EPS beat(2)40.09%
EPS beat(4)4
Avg EPS beat(4)21.37%
Min EPS beat(4)1.51%
Max EPS beat(4)40.09%
EPS beat(8)7
Avg EPS beat(8)13.21%
EPS beat(12)10
Avg EPS beat(12)9.93%
EPS beat(16)10
Avg EPS beat(16)-1.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.94%
PT rev (3m)-10.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)1.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.15
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.03
EV/EBITDA N/A
EPS(TTM)-1.7
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.19
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -131.46%
ROE -356.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.62%
ROA(5y)-102.28%
ROE(3y)-93%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.75%
Cap/Sales 0.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.11
Quick Ratio 3.11
Altman-Z -13.84
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)33.23%
Cap/Depr(5y)66.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.57%
EPS Next Y40.27%
EPS Next 2Y21.82%
EPS Next 3Y13.83%
EPS Next 5Y10.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.03%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.22%
OCF growth 3YN/A
OCF growth 5YN/A